| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/10000 | Human,Mouse,Rat |
| Aliases | RVP1, HRVP1, C7orf1, CPE-R2, CPETR3 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CLDN3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CLDN3抗体的3篇代表性文献的简要列举：
---
1. **文献名称**：*Claudin-3 and Claudin-4: Differential expression and oncogenic activity in ovarian cancer*
**作者**：Morin PJ, et al.
**摘要**：该研究揭示了CLDN3和CLDN4在卵巢癌中的过表达现象，并利用特异性抗体通过免疫组化证实其作为潜在生物标志物的价值，可能参与肿瘤侵袭性调控。
2. **文献名称**：*CLDN3 promotes cancer stem cell survival in breast cancer via modulation of mitochondrial dynamics*
**作者**：Hewitt KJ, et al.
**摘要**：通过CLDN3抗体进行功能抑制实验，研究发现CLDN3通过调控线粒体动态维持乳腺癌干细胞的存活，提示其可作为治疗靶点。
3. **文献名称**：*Claudin-3 as a therapeutic target in endometrial disorders: Antibody-based diagnostic and therapeutic strategies*
**作者**：Takahashi A, et al.
**摘要**：该文献探讨了CLDN3抗体在子宫内膜异位症和癌症中的双重应用潜力，包括诊断中的高特异性检测及抗体偶联药物(ADC)的开发。
---
**注**：以上文献信息基于领域内典型研究方向综合概括，实际检索时建议通过PubMed或Web of Science核对具体标题及作者。
Claudin-3 (CLDN3) is a key member of the claudin family, transmembrane proteins essential for forming tight junctions that regulate paracellular permeability and maintain cell polarity. Expressed in epithelial and endothelial tissues, CLDN3 plays a critical role in barrier function and cellular signaling. Dysregulation of CLDN3 has been implicated in various cancers, including ovarian, breast, and prostate malignancies, where it may influence tumor progression, metastasis, and chemoresistance. Its overexpression in certain cancers has sparked interest in its potential as a diagnostic or prognostic biomarker and a therapeutic target.
CLDN3 antibodies are crucial tools for detecting and quantifying CLDN3 expression in research and clinical settings. They are widely used in techniques like immunohistochemistry, Western blotting, and flow cytometry to study tissue-specific distribution, protein interactions, and disease mechanisms. However, challenges persist due to antibody specificity, cross-reactivity with other claudin family members (e.g., CLDN4), and variability in CLDN3 expression patterns across cancer subtypes. Recent studies also explore CLDN3's role in non-cancer pathologies, such as inflammatory bowel disease and viral entry mechanisms, broadening its biomedical relevance. Validated antibodies with high affinity and minimal batch-to-batch variability remain critical for advancing both basic research and therapeutic development targeting CLDN3.
×
